Post-Market Clinical Follow-up Study with ASPIREX®S to Assess the Safety and Effectiveness in the Treatment of DVT
A legfontosabb adatok
- Ki végzi
- Straub Medical AG
- Hol
- Ausztria, Franciaország, Írország, Németország és Olaszország9 helyszín, 5 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 81 fő vett részt
- Kezdés
- 2017. ápr. 3.
- Befejezés
- 2024. jún. 6.
- A vizsgálat típusa
- Megfigyeléses
- A regiszteradat frissítve
- 2024. december 3.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Acute thrombotic or thromboembolic occlusion (onset of pain < 14 days)
- Age > 18 years
- Written informed consent form
Ki nem vehet részt
- Known, unhealed pre-existing mechanical damage to the vessel wall, especially caused by surgical procedures or interventional complications
- Current participation in any other clinical study (medicinal, medical device) or within the last 30 days prior to screening
- Known or suspected allergy to any of the components of the system or to a medicinal product to be administered in connection with the planned procedure
- Severe coagulatory disorders
- Known or suspected infection, especially of the puncture site or the vessel segment being treated
- Patient not suitable for thrombectomy
- Fracture area of broken stents
- Persistent vasospasm
- Patients with thrombophilia
- Aneurysmatically altered vessel segments on target zone or on passage of catheter
- Immature or not fully healed dialysis accesses or bypass grafts
- Female subjects of childbearing capacity who are not willing to employ contraceptive measures
- Pregnant or breast feeding subjects
- Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with requirements of the study
- Subjects who are lawfully kept in an institution
- Subjects who do not have the mental or physical ability to comply with time schedules and further study procedures
Hol van ez a vizsgálat?
5 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The ASPIREX®S Endovascular System is a rotating and aspirating catheter system. It is intended to be used for the percutaneous transluminal removal of fresh thrombotic or thromboembolic material from native blood vessels (or vessels fitted with stents, stent grafts or native or artificial bypasses) outside the cardiopulmonary, coronary and cerebral circulations.
A teljes eredeti leírásKevesebb
CAPTUREX® , a catheter with a filter basket, is intended to be used for the filtering of emboli from blood vessels during potentially embolizing procedures on the patient.
ASPIREX®S and CAPTUREX® are CE-marked (Class III) medical devices. In this study the effectiveness and safety in the removal of thrombi in veins is assessed under real life setting.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Post-Market Clinical Follow-up Study with the ASPIREX®S Endovascular System to Assess the Safety and Effectiveness in the Treatment of DVT Patients and Special Patient Groups
- A regiszteradat frissítve
- 2024. december 3.